Arrowstreet Capital, Limited Partnership Chemo Centryx, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $2.37 Million - $5.54 Million	106,862 New	106,862 $5.52 Million
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $159,809 - $221,312	-24,700 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$8.31 - $14.85 $2.49 Million - $4.46 Million	-300,048 Reduced 92.39%	24,700 $230,000
Q1 2019 May 15, 2019	BUY	$10.01 - $13.89 $1.05 Million - $1.45 Million	104,744 Added 47.61%	324,748 $4.51 Million
Q4 2018 Feb 14, 2019	BUY	$9.15 - $12.26 $84,564 - $113,306	9,242 Added 4.39%	220,004 $2.4 Million
Q3 2018 Nov 14, 2018	BUY	$10.49 - $13.72 $1.21 Million - $1.58 Million	115,268 Added 120.71%	210,762 $2.66 Million
Q2 2018 Aug 14, 2018	BUY	$10.62 - $13.98 $650,772 - $856,666	61,278 Added 179.09%	95,494 $1.26 Million
Q1 2018 May 14, 2018	BUY	$5.9 - $14.99 $48,380 - $122,918	8,200 Added 31.52%	34,216 $465,000
Q4 2017 Feb 09, 2018	BUY	$5.53 - $8.42 $44,334 - $67,503	8,017 Added 44.54%	26,016 $155,000
Q3 2017 Nov 14, 2017	BUY	$6.5 - $10.69 $116,993 - $192,409	17,999	17,999 $134,000

66.3K

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.